AI Article Synopsis
- Topotecan is the standard treatment for relapsed small-cell lung cancer (SCLC), with both oral and intravenous forms being equally effective, but oral treatment has fewer side effects.
- A case study presented a patient with stable disease after using oral topotecan; however, when switched to intravenous topotecan due to supply issues, the patient experienced significant disease regression after one dose.
- This report highlights the first known instance of intravenous topotecan showing a better response than oral topotecan, with no clear reasons found for this difference.
Article Abstract
Introduction: Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally effective with less adverse events in the oral group.
Case Presentation: We report a case of a patient with SCLC, who had previously received oral topotecan, with radiological stable disease with no changes in tumor or metastasis diameter size after two administrations. Subsequently, this patient received intravenous topotecan instead of oral due to supply difficulties. After one administration of intravenous topotecan, we saw significant disease regression.
Conclusion: This is to our knowledge the first reported case of better response of intravenous topotecan than oral topotecan. Multiple extrinsic (e.g., food, medication) factors were investigated but could not deliver an explanation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521484 | PMC |
| http://dx.doi.org/10.1159/000540861 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!